Mayne Pharma Group Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MYX.AX | 002589.SZ | S1R.F | 1731.TW | CAN.AX | 600993.SS | |
|---|---|---|---|---|---|---|
| Market cap | 221.92M | 4.33B | 4.64B | 2.79B | 8.30M | 10.76B |
| P/E (TTM) | 8.7 | 288.0 | 7.4 | 13.9 | 0.3 | 18.1 |
| Forward P/E | -7.2 | — | — | 19.1 | 0.0 | 16.9 |
| Price/book | 0.6 | 0.8 | 0.4 | 1.3 | 0.3 | 2.4 |
| Dividend yield | — | 0.07% | 4.67% | 5.84% | — | 2.81% |
| 1-year change | −45.98% | −3.73% | −3.85% | −5.64% | −54.55% | −13.34% |
| Today | +3.44% | +1.41% | 0.00% | +0.48% | 0.00% | +0.36% |
The closest companies by business and industry (Medical Distribution). Prices may be delayed up to 20 min.
Latest news
All MYX.AX news ›Mayne Pharma Group Settles Patent Litigation With Sun Pharmaceutical Industries
Mayne Pharma Group settled Paragraph IV patent litigation with Sun Pharmaceutical Industries concerning Imvexxy, an estradiol vaginal insert used to treat moderate to severe menopause-related... Mayne Pharma Group Limited Mayne Pharma…
Mayne Pharma clears another legal hurdle as Teva agrees to 2032 generic entry for Imvexxy
Specialty pharmaceutical company Mayne Pharma (ASX: MYX) has settled the last of its US patent litigation over menopause treatment Imvexxy, agreeing to a 2032 entry date for a generic version from Teva Pharmaceuticals USA. The settlement…
Mayne Pharma resolves IMVEXXY patent dispute with Teva
Assets related to this article Mayne Pharma (ASX:MYX) has settled its US patent litigation with Teva Pharmaceuticals USA over generic versions of the menopause treatment IMVEXXY. The agreement resolves ongoing litigation started in April…
More from 1 other outlet
Mayne Pharma wins dismissal of Cosette appeal over abandoned takeover
The court awarded appeal costs; the A$7.40-a-share deal was terminated in December 2025, and Mayne is pursuing damages. An appeal over termination rights in an abandoned A$7.40-a-share takeover was dismissed on Wednesday as Mayne Pharma…
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover
Here are some of the details: • Cosette bid A$7.40 per share for Mayne in February last year but later tried to back out, saying a deterioration in Mayne’s financial performance constituted a material adverse change that voided the…
More from 1 other outlet
Cosette Pharmaceuticals loses bid to overturn failed material adverse change claim against Mayne Pharma
The news: The NSW Court of Appeal has dismissed Cosette Pharmaceutical’s bid to overturn a decision that halted one of its attempts to walk from an acquisition of Mayne Pharma, although it was later blocked by Treasurer Jim Chalmers. With…
Attorney General Aaron M. Frey Seeks Court Approval for Settlements with Ascend, Citron, and Mayne Pharma Over Conspiracy to Inflate Prices and Limit Competition | Attorney General
FOR IMMEDIATE RELEASEContact: Danna [email protected] You Bought Certain Generic Prescription Drugs in the United States Between May 2009 and December 2019, You Could be Eligible for Money Attorney General Aaron M. Frey Seeks…
Mayne Pharma Group Names CFO
Mayne Pharma Group appointed Griffin Buchanan as its Chief Financial Officer, effective Aug. 1, according to a Friday Australian bourse filing. He was most recently Vice President, Operational... Mayne Pharma Group Limited Mayne Pharma…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- capitalbrief.com2
- marketscreener.com2
- businessnewsaustralia.com1
- grafa.com1
- mugglehead.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.